熱門(mén)詞: 進(jìn)口電動(dòng)溫度調(diào)節(jié)閥結(jié)構(gòu)圖|進(jìn)口電動(dòng)溫度調(diào)節(jié)閥數(shù)據(jù)表進(jìn)口電動(dòng)高溫調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)高溫法蘭調(diào)節(jié)閥進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥-德國(guó)進(jìn)口電動(dòng)蒸汽調(diào)節(jié)閥
美國(guó)Cephalon Inc.
美國(guó)生物制藥商Cephalon Inc.(CEPH) 如今的Cephalon 公司已經(jīng)是一個(gè)擁有3000 名雇員和年銷(xiāo)售額近20 億美元的跨國(guó)生物技術(shù)公司。
致力于為中樞神經(jīng)系統(tǒng),炎癥性疾病,疼痛,腫瘤治療領(lǐng)域發(fā)現(xiàn)、開(kāi)發(fā)產(chǎn)品并使之商業(yè)化。該公司作為以生物技術(shù)開(kāi)發(fā)為主成立于1987年,已經(jīng)成長(zhǎng)為世界十大生物制藥公司之一,以一流的產(chǎn)品,一個(gè)深化和多樣化的管道。
At Cephalon, we never lose sight of why we’re in business: to improve health and enhance the quality of the lives of patients through smart application of science.
Founded in 1987 as a biotech start-up, we have grown into one of the world’s top ten biopharmaceutical companies, with an impressive roster of first-in-class products, a deep and diverse pipeline, and annual revenues of $1.94 billion. And even though we’ve grown to nearly 3,000 employees in locations around the globe, we’ve never lost the agility and nimbleness of a start-up.
Our portfolio of innovative treatments for central nervous system disorders, pain, and cancer include eight proprietary products in the United States, along with more than 30 products internationally. Our research pipeline is focused on developing new compounds and new indications for existing products, while our business collaborations capitalize on new products and smart drug delivery technologies.
The single greatest measure of our success will always be the countless people who benefit from our medications every day. They are our true legacy and why we do what we do.